Hepalys

Executive Summary

Hepalys Pharma is a late-stage clinical biopharmaceutical company headquartered in Tokyo, Japan, dedicated to developing innovative therapies for liver diseases, with a primary focus on metabolic dysfunction-associated steatohepatitis (MASH). The company’s lead asset, lanifibranor, is a first-in-class pan-PPAR agonist that simultaneously modulates metabolic, inflammatory, and fibrotic pathways, targeting the underlying pathophysiology of MASH. Hepalys specifically aims to address the unmet medical needs of Japanese and broader Asian patient populations, who have distinct disease characteristics and metabolic profiles. Lanifibranor has demonstrated promising efficacy and safety in prior trials, and the company is currently advancing it through Phase 3 development. With a lean team of 10–50 employees, Hepalys operates efficiently and benefits from Japan's supportive regulatory environment for innovative therapeutics. The successful development of lanifibranor could position Hepalys as a key player in the rapidly growing MASH treatment market, which currently lacks approved therapies for Asian populations.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Top-Line Data Readout for Lanifibranor in MASH55% success
• Q1 2027Regulatory Submission (NDA) in Japan for Lanifibranor40% success
• Q4 2026Strategic Partnership or Licensing Deal for Asian Commercialization35% success